**Executive Summary**
The 9th edition of PharmaMed 2026 concluded on March 27, 2026, in New Delhi, focusing on India's transition from a volume-driven to a value-driven pharmaceutical ecosystem. Organized by the PHD Chamber of Commerce & Industry and the Department of Pharmaceuticals, the conference established a roadmap for innovation, regulatory harmonization, and global competitiveness. Key action items include strengthening domestic API manufacturing, adopting digital tools like AI for supply chain security, and ensuring healthcare equity through last-mile access.
**Key Points / Main Content**
**Innovation and Leadership**
* Shift the pharmaceutical sector toward high-value innovation, specifically in biologics, biosimilars, and advanced therapies.
* Strengthen biopharmaceutical manufacturing capabilities while balancing innovation with affordability to maintain global competitiveness.
* Align academic research more closely with industry needs and regulatory requirements to foster a value-driven ecosystem.
**Regulatory Harmonization and Quality**
* Improve quality standards across the supply chain through stronger regulatory frameworks and compliance.
* Harmonize regulations between central and state authorities and adopt international global standards.
* Utilize digital tools, such as AI and traceability systems, to ensure end-to-end quality assurance and enhanced pharmacovigilance.
**Supply Chain and Manufacturing**
* Reduce reliance on imported Active Pharmaceutical Ingredients (APIs) and raw materials by strengthening domestic manufacturing.
* Optimize logistics and cold chain infrastructure while upgrading workforce skills to meet modern industry demands.
* Implement AI and advanced technology to streamline supply chains and combat the distribution of counterfeit drugs.
**Distribution and Access**
* Leverage digital transformation and the growth of e-pharmacies to improve last-mile access to medicines.
* Ensure healthcare equity by maintaining a balance between regulation, affordability, and accessibility.
* Coordinate efforts between academia, industry, and government to ensure high-quality medicines reach all citizens.
**Impact Analysis**
**Pharmaceutical Industry (Manufacturers & Biotechs)**
**Impact**
Companies are being pushed to transition from generic volume production to high-value innovation in biologics and advanced therapies. There is also increased pressure to source raw materials domestically.
**Action Required**
Invest in R&D for biosimilars and high-value pharmaceuticals while reducing dependence on imported APIs.
**Regulatory Bodies (Central and State)**
**Impact**
There is an urgent need for the harmonization of varying state and central regulations to meet global compliance standards.
**Action Required**
Implement unified regulatory frameworks, enhance pharmacovigilance, and deploy AI-driven traceability systems.
**Academia and Research Institutions**
**Impact**
Academic institutions are identified as critical partners in the innovation roadmap, requiring a shift in research focus.
**Action Required**
Align research projects with industrial applications and regulatory standards to support the "volume to value" transition.
**Logistics and Distribution Providers (including E-pharmacies)**
**Impact**
Providers are tasked with ensuring the integrity of the supply chain and reaching remote areas through digital transformation.
**Action Required**
Upgrade cold chain infrastructure and adopt digital distribution systems to ensure medicine affordability and prevent counterfeiting.
Key Entities Referenced
PharmaMed 2026: The 9th edition of the national conference focused on charting the future of India’s pharmaceutical sector with a roadmap for innovation, regulation, and healthcare equity.
Department of Pharmaceuticals: The primary government department under the Ministry of Chemicals & Fertilizers responsible for co-organizing the event and overseeing the pharmaceutical sector's transition to a value-driven ecosystem.
Central Drugs Standard Control Organization (CDSCO): India's national regulatory authority that participated in key deliberations on regulatory harmonization, global compliance, and pharmaceutical quality standards.
PHD Chamber of Commerce & Industry: The industry association that organized the conference in collaboration with the government to address supply chain challenges and domestic manufacturing capabilities.
Pharmaceuticals Export Promotion Council of India (Pharmexcil): The nodal agency for promoting pharmaceutical exports, involved in discussions regarding India’s global leadership and competitiveness in high-value pharmaceuticals.
Ministry of Chemicals and Fertilizers :
Department of Pharmaceuticals
PharmaMed 2026 Concludes
India Charts Future of Pharma at PharmaMed 2026 with
Emphasis on Resilience, Regulation, and Healthcare for All
Roadmap to Equitable, Innovative and Globally Competitive
Pharmaceutical Sector discussed at the Conference
Posted On: 27 MAR 2026 8:24PM by PIB Delhi
The 9th edition of PharmaMed 2026, organized by the PHD Chamber of Commerce & Industry in
collaboration with the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Government
of India, concluded in New Delhi today. Following a high-impact inaugural session in the morning, the
conference featured four thematic sessions, where industry leaders, policymakers, regulators, and
stakeholders engaged in in-depth deliberations on key priority areas shaping the future of India’s
pharmaceutical sector.
The discussions underscored India’s transition from a volume-driven to a value-driven pharmaceutical
ecosystem, with a strong focus on innovation, quality, resilience, and last-mile access.
Speakers highlighted the need to drive innovation in high-value pharmaceuticals, biologics, and advanced
therapies while building robust capabilities in biosimilars and biopharmaceutical manufacturing.Session on ‘Redefining India’s Pharmaceutical Leadership - From Volume to Value’ witnessed
participation from CDSCO, PharmaExil, Cipla, NIPER. It focused on shifting India’s pharmaceutical
sector toward high-value innovation. Discussions emphasized strengthening research in biologics,
advanced therapies, and biosimilars, while aligning academic research with industry and regulatory needs.
The importance of integrating quality from the early stages and balancing innovation with affordability to
maintain global competitiveness was stressed by the speakers.
Delegates stressed on improving quality standards across the supply chain through stronger regulatory
frameworks and compliance in the session on ‘Strengthening Pharmaceutical Quality – Regulatory
Harmonization & Global Compliance’ . They also underscored the need for harmonization between
central and state regulations, adoption of global standards, enhanced pharmacovigilance, and the use of
digital tools such as AI and traceability systems to ensure end-to-end quality assurance.
Session on ‘Supply Chain Challenges in Pharma & Tackling Counterfeit Drugs’ had speakers from
Mankind Pharma, Safeexpress Private. They stressed the need to reduce dependence on imports for APIs
and raw materials while strengthening domestic manufacturing. The session also highlighted improving
logistics, cold chain infrastructure, and workforce skills. The role of technology, especially AI, in
optimizing supply chains and combating counterfeit drugs was emphasized.Session on ‘Last-Mile Access to Medicines – Strengthening Distribution & Affordability,’ focused on
improving access to medicines through digital transformation and efficient distribution systems.
Discussions highlighted the growing role of e-pharmacies, the need for balanced regulation, and the
importance of ensuring affordability and accessibility to achieve healthcare equity across the country.
Leading organizations and industry stakeholders, including Central Drugs Standard Control Organization,
Pharmexcil, Cipla, AstraZeneca, Organisation of Pharmaceutical Producers of India, Serum Institute of
India, Biotechnology Industry Research Assistance Council, National Institute of Pharmaceutical
Education and Research Mohali, United States Food and Drug Administration, Tenet Health Edutech Pvt
Ltd, NuLifeCare, Daund Biological, EVERSANA, Jamia Hamdard, Mankind Pharma, Apollo Pharmacy,
Tata 1mg, and Association of Healthcare Providers India actively participated in the sessions, contributing
diverse expertise and valuable insights through the sessions.
Overall, PharmaMed 2026 highlighted India’s commitment to building a future-ready pharmaceutical
sector that balances innovation with inclusivity. The conference reinforced that achieving healthcare
equity will require coordinated efforts across academia, industry, and government, ensuring that high-
quality, affordable medicines reach every citizen while strengthening India’s global leadership in
pharmaceuticals.****
PC/PM
(Release ID: 2246290) Visitor Counter : 138
Read this release in: ही , Urdu